The NHS in England will offer thousands of men with prostate cancer the life-prolonging drug abiraterone, which blocks hormones such as testosterone needed for tumor growth.[1] The treatment will be available for the first time to patients whose cancer has not yet spread beyond the prostate, including about 2,000 men diagnosed in the past three months, if it is clinically beneficial.[1] Each year, an additional 7,000 men with newly diagnosed high-risk prostate cancer will be eligible for the drug.[1] Scotland and Wales already offer the drug as the first advanced local option after the patent expires in 2022, when the price drops to a generic.[1] Research has shown that after six years, 86% of men on abiraterone survived compared to 77% on standard hormone therapy with or without radiotherapy.[1] NHS England introduced the treatment for advanced prostate cancer in December 2024, ahead of the NICE recommendation in November 2025.[1] The decision came after a three-year campaign by Prostate Cancer UK against inequalities in access by region.[1]